. Author manuscript; available in PMC: 2018 Dec 1.

Published in final edited form as: Mol Diagn Ther. 2017 Dec;21(6):621–631. doi: 10.1007/s40291-017-0292-x

TABLE 1.

Drug metabolism variants that influence TKI response in CML patients

Genes	Variants	Drug	References
CYP3A5	CYP3A5*3 (GG)	Imatinib	[29]
CYP2B6	15631 (GG/TT)	Imatinib	[30]
UGT1A1	UGT1A128 UGT1A16	Nilotinib	[38–40]